NZ546931A - Method for synthesis of perindopril and the pharmaceutically acceptable salts thereof - Google Patents
Method for synthesis of perindopril and the pharmaceutically acceptable salts thereofInfo
- Publication number
- NZ546931A NZ546931A NZ546931A NZ54693104A NZ546931A NZ 546931 A NZ546931 A NZ 546931A NZ 546931 A NZ546931 A NZ 546931A NZ 54693104 A NZ54693104 A NZ 54693104A NZ 546931 A NZ546931 A NZ 546931A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- process according
- formula
- dba
- synthesis process
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03292864A EP1420028B1 (fr) | 2003-11-19 | 2003-11-19 | Pocédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables |
PCT/FR2004/002936 WO2005054276A1 (fr) | 2003-11-19 | 2004-11-18 | Procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ546931A true NZ546931A (en) | 2010-01-29 |
Family
ID=32116380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ546931A NZ546931A (en) | 2003-11-19 | 2004-11-18 | Method for synthesis of perindopril and the pharmaceutically acceptable salts thereof |
Country Status (29)
Country | Link |
---|---|
US (1) | US7208607B1 (zh) |
EP (1) | EP1420028B1 (zh) |
JP (1) | JP4377412B2 (zh) |
KR (1) | KR100863394B1 (zh) |
CN (1) | CN100447152C (zh) |
AR (1) | AR047312A1 (zh) |
AT (1) | ATE354586T1 (zh) |
AU (1) | AU2004295132B2 (zh) |
BR (1) | BRPI0416746B1 (zh) |
CA (1) | CA2546506C (zh) |
CY (1) | CY1106544T1 (zh) |
DE (1) | DE60311942T2 (zh) |
DK (1) | DK1420028T3 (zh) |
EA (1) | EA010102B1 (zh) |
EG (1) | EG26629A (zh) |
ES (1) | ES2282586T3 (zh) |
GE (1) | GEP20084547B (zh) |
HK (1) | HK1096689A1 (zh) |
MA (1) | MA28144A1 (zh) |
MX (1) | MXPA06005607A (zh) |
MY (1) | MY138550A (zh) |
NO (1) | NO336349B1 (zh) |
NZ (1) | NZ546931A (zh) |
PL (1) | PL210769B1 (zh) |
PT (1) | PT1420028E (zh) |
SI (1) | SI1420028T1 (zh) |
UA (1) | UA83269C2 (zh) |
WO (1) | WO2005054276A1 (zh) |
ZA (1) | ZA200603675B (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE310012T1 (de) * | 2003-08-29 | 2005-12-15 | Servier Lab | Verfahren für die synthese von perindopril und seiner pharmazeutisch annehmbaren salzen |
CZ2006427A3 (cs) | 2003-12-29 | 2006-11-15 | Sepracor Inc. | Pyrrolové a pyrazolové inhibitory DAAO |
MX2008000250A (es) | 2005-07-06 | 2008-03-19 | Sepracor Inc | Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y |
KR101381768B1 (ko) | 2006-01-06 | 2014-04-07 | 선오비온 파마슈티컬스 인코포레이티드 | 테트랄론-기재 모노아민 재흡수 저해제 |
CA2636324C (en) | 2006-01-06 | 2012-03-20 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
ES2643602T3 (es) | 2006-03-31 | 2017-11-23 | Sunovion Pharmaceuticals Inc. | Aminas y quirales |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
CN103936605B (zh) | 2007-05-31 | 2017-09-01 | 赛诺维信制药公司 | 苯基取代的环烷胺作为一元胺再摄取抑制剂 |
WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
FR3050380B1 (fr) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
CN112047869B (zh) * | 2020-08-20 | 2021-12-21 | 华南理工大学 | 一种氮杂5,6-并环化合物的合成方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2620709B1 (fr) * | 1987-09-17 | 1990-09-07 | Adir | Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese |
-
2003
- 2003-11-19 SI SI200330702T patent/SI1420028T1/sl unknown
- 2003-11-19 DK DK03292864T patent/DK1420028T3/da active
- 2003-11-19 ES ES03292864T patent/ES2282586T3/es not_active Expired - Lifetime
- 2003-11-19 AT AT03292864T patent/ATE354586T1/de active
- 2003-11-19 EP EP03292864A patent/EP1420028B1/fr not_active Expired - Lifetime
- 2003-11-19 DE DE60311942T patent/DE60311942T2/de not_active Expired - Lifetime
- 2003-11-19 PT PT03292864T patent/PT1420028E/pt unknown
-
2004
- 2004-11-18 AR ARP040104252A patent/AR047312A1/es not_active Application Discontinuation
- 2004-11-18 US US10/580,148 patent/US7208607B1/en not_active Expired - Fee Related
- 2004-11-18 GE GEAP20049463A patent/GEP20084547B/en unknown
- 2004-11-18 KR KR1020067011929A patent/KR100863394B1/ko not_active IP Right Cessation
- 2004-11-18 BR BRPI0416746-5A patent/BRPI0416746B1/pt not_active IP Right Cessation
- 2004-11-18 UA UAA200606747A patent/UA83269C2/uk unknown
- 2004-11-18 CA CA2546506A patent/CA2546506C/fr not_active Expired - Fee Related
- 2004-11-18 CN CNB2004800336869A patent/CN100447152C/zh not_active Expired - Fee Related
- 2004-11-18 PL PL380409A patent/PL210769B1/pl unknown
- 2004-11-18 EA EA200600898A patent/EA010102B1/ru not_active IP Right Cessation
- 2004-11-18 MX MXPA06005607A patent/MXPA06005607A/es active IP Right Grant
- 2004-11-18 ZA ZA200603675A patent/ZA200603675B/en unknown
- 2004-11-18 JP JP2006540515A patent/JP4377412B2/ja not_active Expired - Fee Related
- 2004-11-18 AU AU2004295132A patent/AU2004295132B2/en not_active Ceased
- 2004-11-18 WO PCT/FR2004/002936 patent/WO2005054276A1/fr active Application Filing
- 2004-11-18 NZ NZ546931A patent/NZ546931A/en not_active IP Right Cessation
- 2004-11-18 MY MYPI20044785A patent/MY138550A/en unknown
-
2006
- 2006-05-02 MA MA28993A patent/MA28144A1/fr unknown
- 2006-05-16 EG EGPCTNA2006000459A patent/EG26629A/en active
- 2006-06-06 NO NO20062599A patent/NO336349B1/no not_active IP Right Cessation
-
2007
- 2007-02-01 HK HK07101194.5A patent/HK1096689A1/xx not_active IP Right Cessation
- 2007-04-26 CY CY20071100562T patent/CY1106544T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO336349B1 (no) | Mellomproduktet og fremgangsmåte for syntese av perindopril og farmasøytisk akseptable salter derav | |
US7223872B2 (en) | Process for the synthesis of perindopril and its pharmaceutically acceptable salts | |
NZ521324A (en) | A process for the synthesis of N-[(S)-1-carboxybutyl]- (S)-alanine esters and use in synthesis of perindopril and its salts | |
US7183308B1 (en) | Metod for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
US7534896B2 (en) | Process for the synthesis of perindopril and its pharmaceutically acceptable salts | |
US7358372B2 (en) | Method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
US7368580B2 (en) | Method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
PT1422236E (pt) | Processo de síntese do perindopril e dos seus sais farmacêuticamente aceitáveis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 NOV 2017 BY AJ PARK Effective date: 20140814 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2018 BY AJ PARK Effective date: 20171103 |
|
LAPS | Patent lapsed |